Phase II evaluation of Ly156758 in metastatic breast cancer.
Fourteen patients with disseminated breast cancer with primary or secondary resistance to tamoxifen were treated with LY156758. There were no complete or partial responses and 1 patient showed a minor response. These data illustrate that LY156758 did not have significant antitumor activity in patients previously treated with tamoxifen therapy.
Buzdar
A U
AU
Department of Medical Oncology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston.
Marcus
C
C
Holmes
F
F
Hug
V
V
Hortobagyi
G
G
D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D010880:Piperidines / Q000627:therapeutic use*; D020849:Raloxifene Hydrochloride
D004965:Estrogen Antagonists; D010880:Piperidines; D020849:Raloxifene Hydrochloride